Valuation : Aprea Therapeutics, Inc.

Market Cap 10.83M 9.3M 8.7M 7.97M 15.01M 1.03B 15.06M 103M 40.29M 521M 40.66M 39.78M 1.73B P/E 2026 *
-2.8x
P/E 2027 * -3.04x
Enterprise Value 10.83M 9.3M 8.7M 7.97M 15.01M 1.03B 15.06M 103M 40.29M 521M 40.66M 39.78M 1.73B EV / Sales 2026 *
26.5x
EV / Sales 2027 * 9.57x
Free-Float
83.56%
Yield 2026 *
-
Yield 2027 * -
08-12 Aprea Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-12 Wedbush Adjusts Aprea Therapeutics Price Target to $3 From $6, Maintains Outperform Rating MT
07-30 Aprea Therapeutics, Inc. Provides Update On ACESOT-1051 Program For WEE1 Inhibitor APR-1051 And Expands Clinical Development CI
05-15 Aprea Therapeutics - files for resale of up to 5.5 million shares by selling stockholders - SEC filing RE
05-14 Wedbush Adjusts Price Target on Aprea Therapeutics to $6 From $7, Maintains Outperform Rating MT
05-13 Aprea Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-07 Oppenheimer Initiates Aprea Therapeutics at Outperform With $5 Price Target MT
03-30 Aprea Therapeutics, Inc. announced that it has received $30.0204 million in funding from Soleus Capital LLC, Vestal Point Capital, LP, Squadron Capital Management Llc CI
03-30 Aprea Therapeutics, Inc. announced that it expects to receive $30.0204 million in funding from Soleus Capital LLC, Vestal Point Capital, LP, Squadron Capital Management Llc and other investors CI
03-30 Aprea Therapeutics Announces Positive Emerging Clinical Activity for Wee1 Inhibitor Apr-1051 with Confirmed Partial Response in Ongoing Phase 1 Acesot-1051 Trial CI
03-30 Aprea Therapeutics highlights positive emerging clinical activity for WEE1 inhibitor, APR-1051 RE
03-16 Aprea Therapeutics Q4 eps usd -0.32 RE
03-16 Aprea Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 CI
1 day-12.23%
1 week+34.38%
Current month+38.73%
1 month+37.68%
3 months-5.96%
6 months-6.17%
Current year+0.83%
1 week 0.68
Extreme 0.6801
1.16
1 month 0.59
Extreme 0.5901
1.16
Current year 0.55
Extreme 0.548
1.49
1 year 0.55
Extreme 0.548
1.69
3 years 0.55
Extreme 0.548
8.85
5 years 0.55
Extreme 0.548
25.8
10 years 0.55
Extreme 0.548
25.8
Manager TitleAgeSince
Chief Executive Officer 57 2022-06-28
Director of Finance/CFO 62 2023-01-29
Corporate Officer/Principal 58 2023-10-31
Director TitleAgeSince
Director/Board Member 69 2014-12-31
Director/Board Member 64 2019-07-31
Chairman 63 2023-08-22
Date Insider Type Main position Quantity % Market Cap.
6/16/26 Free

Director

15,690 0.1267%
1/30/26 Buy

Chief Financial Officer

11,400 0.1630%
1/30/26 Buy

Chief Executive Officer

56,200 0.8036%
Change 5-day change 1-year change 3-year change Capi.($)
-12.23%+34.38%-46.24%-76.37% 10.83M
+3.31%-3.70%+61.03%+103.64% 70.64B
-0.22%+0.40%+50.28%+92.84% 66.11B
-1.03%+0.46%+8.14%-5.28% 27.98B
-2.41%-2.95%-9.77%+455.82% 26.51B
+0.30%-0.69%+63.18%+11.93% 26.44B
+1.02%+6.43%+269.42%+420.34% 20.4B
+0.46%+1.30%+35.13%-17.15% 20.17B
-1.91%-4.37%+13.33%+531.29% 15.99B
-1.50%+2.92%+43.50%+151.30% 13.69B
Average -1.42%+4.33%+48.80%+166.84% 28.79B
Weighted average by Cap. +0.40%+0.65%+56.57%+154.57%

Financials

2026 *2027 *
Net sales 408K 351K 328K 301K 566K 39.01M 568K 3.89M 1.52M 19.66M 1.53M 1.5M 65.08M 1.13M 971K 909K 833K 1.57M 108M 1.57M 10.77M 4.21M 54.46M 4.25M 4.16M 180M
Net income -15.25M -13.09M -12.25M -11.22M -21.14M -1.46B -21.2M -145M -56.72M -734M -57.25M -56.01M -2.43B -19.24M -16.52M -15.47M -14.16M -26.68M -1.84B -26.75M -183M -71.59M -926M -72.25M -70.69M -3.07B
Net Debt - -
Logo Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company’s pipeline includes two clinical-stage synthetic lethality programs. Its lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small-molecule ATR inhibitor, both in clinical development for solid tumor indications. Its ATRN-119 is an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR). The ATR kinase is a master regulator of Deoxyribonucleic Acid (DNA) damage response, with roles in cell cycle control and DNA repair following replication stress. It is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute. It also has an early-stage program, in the lead optimization stage, for an undisclosed DNA-damage response (DDR) target.
Employees
-
Date Price Change Volume
26-08-27 US$0.8601 -12.23% 1,181,958
26-08-26 US$0.9800 +3.17% 2,818,694
26-08-25 US$0.9499 +17.97% 2,148,901
26-08-24 US$0.8052 +25.75% 2,803,206
26-08-21 US$0.6403 +0.04% 14,845
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.8601USD
Average target price
3.550USD
Spread / Average Target
+312.74%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. APRE Stock